What are the treatment approaches for acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia?

How Leukemia is Treated

Treatment for leukemia is fundamentally different across the four major subtypes—acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML)—with each requiring distinct therapeutic approaches based on disease biology, patient age, and risk stratification.

Acute Lymphoblastic Leukemia (ALL)

Pediatric ALL Treatment Approach

For children with ALL, use risk-adapted multiagent chemotherapy with treatment phases including induction, consolidation, and maintenance over 2-3 years, achieving 80-90% long-term survival 1.

Induction Phase

• Standard backbone: Vincristine + corticosteroid (dexamethasone preferred over prednisone for better CNS penetration) + asparaginase ± anthracycline 1, 2
• NCI standard-risk patients receive 3-drug induction (without anthracyclines)
• Higher-risk patients receive 4-drug regimen adding anthracycline
• Dexamethasone significantly reduces CNS relapse risk compared to prednisone, though carries higher toxicity including osteonecrosis and infection 1

Risk Stratification Determines Subsequent Therapy

• MRD assessment at end of induction (EOI) is critical: MRD ≥0.01% post-consolidation (weeks 9-12) indicates consideration for allogeneic hematopoietic stem cell transplantation (HCT) 1
• High-risk features requiring HCT consideration: MLL/KMT2A mutations in infants <6 months, unfavorable cytogenetics, persistent MRD positivity 1

Consolidation and Maintenance

• Multiple intensification phases with CNS prophylaxis integrated throughout
• Maintenance therapy continues for total treatment duration of 2-3 years 1

Adult ALL Treatment Approach

For adults with Ph-negative B-ALL, use pediatric-inspired regimens or hyper-CVAD with incorporation of immunotherapies (blinatumomab, inotuzumab ozogamicin) to achieve MRD negativity and improve survival to 80-85% at 4 years 3, 4.

First-Line Treatment

• Induction with vincristine + anthracycline + corticosteroid backbone 5, 3
• Novel approach: Combine chemotherapy with blinatumomab or inotuzumab ozogamicin to improve MRD negativity rates 4
• Age ≥60 years: Consider inotuzumab ozogamicin and blinatumomab in lieu of intensive chemotherapy for improved safety 4

Ph-Positive ALL

Add BCR-ABL1 tyrosine kinase inhibitor (TKI) to chemotherapy backbone or combine with blinatumomab, achieving 5-year survival >80% 4. Achieving complete molecular remission by next-generation sequencing may allow patients to avoid allogeneic HCT 4.

T-Cell ALL

Use pegylated asparaginase and nelarabine-containing regimens 4. Early T-cell precursor (ETP) ALL is high-risk requiring allogeneic HCT consideration; venetoclax addition is under investigation 4.

Acute Myeloid Leukemia (AML)

Fit Patients Eligible for Intensive Therapy

For newly diagnosed AML patients <60 years eligible for standard induction, use 7+3 (7 days cytarabine + 3 days anthracycline) with gemtuzumab ozogamicin (GO) added for CD33-positive disease, particularly in core binding factor (CBF) AML where GO improves 6-year survival by 20.7% to 75.5% 6.

Induction Regimen Selection

• Standard 7+3: 7 days standard-dose cytarabine + 3 days daunorubicin 6
• Add GO (3 mg/m² on days 1,4,7) for CD33-positive AML, especially CBF-AML 6
• Therapy-related AML (tAML) or MDS-related AML (MRC-AML) in patients ≥60 years: Use CPX-351 (liposomal daunorubicin/cytarabine), which improved 2-year survival by 18.8% to 31.1% 6

Post-Remission Therapy Based on Risk Stratification

• Favorable-risk (CBF-AML): High-dose cytarabine consolidation or autologous HCT 6
• Intermediate-risk: Consider allogeneic HCT if MRD-positive after consolidation 6
• Adverse-risk: Allogeneic HCT in first complete remission 6

Critical caveat: Allow 2-month interval between last GO dose and allogeneic HCT conditioning to reduce hepatic sinusoidal obstruction syndrome risk, but do not delay transplant if GO given within 8 weeks 6.

Older Adults or Unfit Patients

For patients ≥60 years or those with significant comorbidities, use venetoclax-based regimens over monotherapy, incorporating FLT3 inhibitors or IDH inhibitors when appropriate mutations are present 7.

• Venetoclax + hypomethylating agent (azacitidine or decitabine) is preferred over low-dose cytarabine or hypomethylating agent monotherapy 7
• Add targeted therapy: FLT3 inhibitors for FLT3-mutated AML, IDH inhibitors for IDH1/IDH2-mutated disease 7

Chronic Lymphocytic Leukemia (CLL)

When to Treat

Observe asymptomatic patients regardless of risk category; initiate treatment only for symptomatic disease with bulky/progressive lymphadenopathy, cytopenias not from autoimmune causes, or B symptoms 8.

Approximately 70-80% of patients are asymptomatic at diagnosis, and one-third never require treatment 9.

First-Line Treatment for Symptomatic Disease

For physically fit patients requiring treatment, use fludarabine + cyclophosphamide (FC) combination, which induces higher complete remission rates and longer progression-free survival than chlorambucil or purine analog monotherapy 8.

Modern Targeted Therapy Approach

Current standard involves either continuous BTK inhibitor therapy or time-limited venetoclax + obinutuzumab 9:

• BTK inhibitors (use indefinitely):

  • Acalabrutinib: 88% survival at 4 years
  • Zanubrutinib: 94% survival at 2 years
  • Ibrutinib: 78% survival at 7 years 9

• Venetoclax + obinutuzumab: Fixed duration (1 year), 82% survival at 5 years 9

There is no evidence that starting either class before the other improves outcomes 9.

Special Populations

• Del(17p) patients: Alemtuzumab monotherapy or combination therapy; consider allogeneic HCT as first-line 8
• Significant comorbidity/renal insufficiency: Chlorambucil or dose-reduced fludarabine monotherapy 8

Second-Line and Beyond

• After BTK inhibitor failure: Pirtobrutinib (noncovalent BTK inhibitor) shows >70% overall response rate 9
• After both BTK inhibitor and venetoclax failure: PI3K inhibitors (idelalisib, duvelisib) with close monitoring for autoimmune conditions and infections 9
• Multiple relapses: CAR T-cell therapy (lisocabtagene maraleucel) achieves 45% complete response rate 9
• Curative intent: Allogeneic HCT remains the only potential cure 8, 9

Chronic Myeloid Leukemia (CML)

While not extensively covered in the provided guidelines, CML treatment centers on BCR-ABL1 tyrosine kinase inhibitors as first-line therapy, with allogeneic HCT reserved for TKI-resistant disease or blast crisis.

Key Treatment Principles Across All Leukemias

1. Risk stratification drives therapy intensity: Use cytogenetics, molecular markers, and MRD assessment to guide treatment decisions
2. Age-adapted approaches: Pediatric-inspired regimens improve outcomes in AYA patients with ALL; older adults require less intensive approaches
3. MRD monitoring: Achieving MRD negativity predicts superior outcomes and may obviate need for HCT in some cases
4. Allogeneic HCT: Remains curative option for high-risk disease, refractory disease, or specific genetic abnormalities
5. Targeted therapies: Incorporate when specific mutations present (BCR-ABL1, FLT3, IDH, CD33, CD20, CD19)